DK0680513T3 - Målretning af immunogener med lysosomer - Google Patents

Målretning af immunogener med lysosomer

Info

Publication number
DK0680513T3
DK0680513T3 DK94910648T DK94910648T DK0680513T3 DK 0680513 T3 DK0680513 T3 DK 0680513T3 DK 94910648 T DK94910648 T DK 94910648T DK 94910648 T DK94910648 T DK 94910648T DK 0680513 T3 DK0680513 T3 DK 0680513T3
Authority
DK
Denmark
Prior art keywords
endosomal
lysosomal
antigens
compartment
chimeric
Prior art date
Application number
DK94910648T
Other languages
English (en)
Inventor
J Thomas August
Drew M Pardoll
Frank G Guarnieri
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of DK0680513T3 publication Critical patent/DK0680513T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK94910648T 1993-01-22 1994-01-21 Målretning af immunogener med lysosomer DK0680513T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/006,845 US5633234A (en) 1993-01-22 1993-01-22 Lysosomal targeting of immunogens
PCT/US1994/000588 WO1994017192A2 (en) 1993-01-22 1994-01-21 Lysosomal targeting of immunogens

Publications (1)

Publication Number Publication Date
DK0680513T3 true DK0680513T3 (da) 1999-12-27

Family

ID=21722901

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94910648T DK0680513T3 (da) 1993-01-22 1994-01-21 Målretning af immunogener med lysosomer

Country Status (10)

Country Link
US (1) US5633234A (da)
EP (1) EP0680513B1 (da)
JP (1) JP3581366B2 (da)
AT (1) ATE180835T1 (da)
CA (1) CA2154445C (da)
DE (1) DE69418856T2 (da)
DK (1) DK0680513T3 (da)
ES (1) ES2132395T3 (da)
GR (1) GR3031026T3 (da)
WO (1) WO1994017192A2 (da)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US6051237A (en) † 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
DE19534170C1 (de) * 1995-09-14 1997-04-10 Univ Tuebingen Rekombinantes Polypeptid basierend auf der Primärsequenz der invarianten Kette mit mindestens einer Primärsequenz von einem spezifischen T-Zellepitop oder eines Proteinderivats und dieses rekombinante Polypeptid kodierende Nukleinsäuren
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
CA2259140C (en) * 1996-07-10 2008-09-30 Immunex Corporation Method of activating dendritic cells
US6294378B1 (en) * 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
CA2268752A1 (en) * 1996-10-23 1998-04-30 The Trustees Of The University Of Pennsylvania Plasmids encoding immunogenic proteins and intracellular as follows
US6087174A (en) * 1996-12-26 2000-07-11 Johns Hopkins University, School Of Medicine Growth medium for primary pancreatic tumor cell culture
US7098306B2 (en) * 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
JP3816959B2 (ja) * 1997-02-13 2006-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 肝細胞癌の予防および処置
US6054133A (en) * 1997-07-10 2000-04-25 The Regents Of The University Of California Anti-microbial targeting for intracellular pathogens
WO1999029883A2 (en) * 1997-12-03 1999-06-17 The Johns Hopkins University Targeting antigen-specific t cells for specific immunotherapy of autoimmune disease
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP2002506886A (ja) * 1998-03-20 2002-03-05 ジェンザイム・コーポレーション 抗腫瘍免疫亢進
US7014848B1 (en) 1998-03-20 2006-03-21 Genzyme Corporation Enhanced anti-tumor immunity
AU4078599A (en) * 1998-05-13 1999-11-29 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
ES2371432T3 (es) * 1998-05-13 2012-01-02 Epimmune Inc. Vectores de expresión para estimular una respuesta inmune y procedimientos de uso de los mismos.
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6667037B1 (en) * 1998-10-09 2003-12-23 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
US20040171980A1 (en) * 1998-12-18 2004-09-02 Sontra Medical, Inc. Method and apparatus for enhancement of transdermal transport
ATE312623T1 (de) * 1999-04-08 2005-12-15 Univ Johns Hopkins Antigen-spezifische induktion der peripheren immuntoleranz
US6849272B1 (en) * 1999-04-21 2005-02-01 Massachusetts Institute Of Technology Endosomolytic agents and cell delivery systems
AU2007201619B2 (en) * 1999-09-16 2011-05-12 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US20030077263A1 (en) * 1999-10-29 2003-04-24 Immunex Corporation Method of activating dendritic cells
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
AU2001255196A1 (en) 2000-03-29 2001-10-08 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
JP2004513615A (ja) 2000-06-28 2004-05-13 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US8318173B2 (en) * 2001-04-05 2012-11-27 The John Hopkins University Chimeric vaccines
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
EP1974752B1 (en) * 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subcellular targeting of therapeutic proteins
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
CA2476755C (en) 2001-12-17 2014-08-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
ES2279849T3 (es) * 2002-10-11 2007-09-01 Imvision Gmbh Moleculas transportadoras de antigenos modulares (moleculas mat) para la modulacion de reacciones inmunitarias, constructos, procedimientos y usos de las mismas.
DE60332377D1 (de) * 2002-10-21 2010-06-10 Eisai Inc Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
AU2003295881A1 (en) * 2002-11-25 2004-06-18 Exelixis, Inc. Lamps as modifiers of the p53 pathway and methods of use
HUE026376T2 (en) 2003-01-06 2016-05-30 Corixa Corp Certain aminoalkyl glucosamide phosphate compounds and their use
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
EP1608675B1 (en) * 2003-03-28 2011-08-17 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use
JP4914224B2 (ja) * 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント
WO2006009011A1 (ja) * 2004-07-15 2006-01-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute コロナウイルススパイクｓ１融合蛋白及びその発現ベクター
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US20070269457A1 (en) * 2006-05-16 2007-11-22 The Buck Institute For Age Research Immunotherapeutic compositions and methods
EP2476435B1 (en) * 2006-08-11 2017-12-20 Life Sciences Research Partners VZW Immunogenic peptides and their use in immune disorders
PT2977456T (pt) 2006-08-15 2018-02-05 Univ Pennsylvania Composições compreendendo hmw-maa e seus fragmentos para tratamento do cancro
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
CA2669347A1 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
AU2008245585B2 (en) 2007-04-27 2011-10-06 Echo Therapeutics, Inc. Skin permeation device for analyte sensing or transdermal drug delivery
EP2612868B1 (en) 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
AU2009214038B2 (en) 2008-02-14 2013-08-22 Katholieke Universiteit Leuven Elimination of immune responses to viral vectors
EP2244733B1 (en) * 2008-02-14 2015-06-17 Life Sciences Research Partners VZW Immunotherapy targeting intracellular pathogens
ES2676630T3 (es) 2008-02-14 2018-07-23 Life Sciences Research Partners Vzw Control inmunogénico de tumores y células tumorales
US20110111395A1 (en) 2008-02-14 2011-05-12 Jean-Marie Saint-Remy Cd4+cells with cytolytic properties
AU2009244148B2 (en) 2008-05-07 2014-10-09 Biomarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
EP2853269B1 (en) 2008-05-19 2019-05-01 Advaxis, Inc. Dual delivery system for heterologous antigens comprising a recombinant Listeria strain attenuated by mutation of dal/dat and deletion of ActA comprising a nucleic acid molecule encoding an listeriolysin O - prostate specific anigen fusion protein
EP2403935B1 (en) 2009-03-04 2017-05-10 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
KR101815716B1 (ko) 2009-04-22 2018-01-05 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 만성 폐쇄성 폐 질환 및 천식의 치료에 사용하기 위한 조성물
ES2569514T3 (es) 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CN103282048B (zh) 2010-10-01 2017-05-17 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
WO2012069568A2 (en) 2010-11-25 2012-05-31 Imnate Sarl Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
US10058599B2 (en) 2012-03-12 2018-08-28 Advaxis, Inc. Suppressor cell function inhibition following Listeria vaccine treatment
CN104519896B (zh) 2012-06-15 2017-11-10 免疫治疗有限公司 用于治疗变态反应的核酸
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CA2943690A1 (en) 2014-03-31 2015-10-08 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP4276106A3 (en) 2015-05-13 2024-01-24 The United States of America as represented by the Secretary of the Department of Health and Human Services Methods and compositions for inducing an immune response using conserved element constructs
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3297680A2 (en) 2015-05-20 2018-03-28 Yeda Research and Development Co. Ltd Method of targeting senescent cells
US11787849B2 (en) 2015-09-25 2023-10-17 Imcyse Sa Methods and compounds for eliminating immune responses to therapeutic agents
CA2999930A1 (en) 2015-09-30 2017-04-06 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof in animals
AU2017252192C1 (en) 2016-04-19 2023-06-08 Imcyse Sa Novel immunogenic CD1d binding peptides
WO2018093932A2 (en) 2016-11-16 2018-05-24 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
JP7610349B2 (ja) 2017-04-22 2025-01-08 イミュノミック セラピューティックス， インコーポレイテッド 改良ｌａｍｐ構築物
JP7222915B2 (ja) 2017-05-02 2023-02-15 イミュノミック セラピューティックス， インコーポレイテッド 癌抗原を含む改善されたｌａｍｐ構築物
CA3066932A1 (en) * 2017-07-04 2019-01-10 Curevac Ag Novel nucleic acid molecules
BR112020023031A2 (pt) 2018-05-11 2021-02-09 Astellas Pharma Inc. ácido nucleico para tratar alergia a crustáceo
CA3099495A1 (en) 2018-05-11 2019-11-14 Astellas Pharma Inc. Nucleic acid for treating mite allergy
CA3100004A1 (en) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
WO2021046243A2 (en) 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
US20240108703A1 (en) 2019-10-18 2024-04-04 Immunomic Therapeutics, Inc. Improved LAMP Constructs Comprising Cancer Antigens
GB2608279B (en) * 2019-12-11 2024-08-28 Myeloid Therapeutics Inc Therapeutic cell compositions and methods for manufacture and uses thereof
MX2023005201A (es) 2020-11-04 2023-06-28 Myeloid Therapeutics Inc Composiciones de proteinas de fusion quimerica modificadas por ingenieria y metodos de uso de las mismas.
WO2022197949A2 (en) 2021-03-17 2022-09-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
FI20237105A1 (en) 2023-05-29 2024-11-30 Onni Biotechnologies Oy Modified natural killer cells with enhanced cytotoxic action and greater survival

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237115A (en) * 1977-11-23 1980-12-02 Bactex, Inc. Method of immunization against enterotoxogenic infection by Escherichia coli
US4397844A (en) * 1978-02-24 1983-08-09 Ciba-Geigy Corporation Antigen derivatives and processes for their preparation
GB2026340B (en) * 1978-07-03 1982-12-22 Ash P Stabilising microvesicles
US4406885A (en) * 1978-12-28 1983-09-27 Research Corporation Preparation of native oncornavirus envelope subunits and vaccines therefrom
DE3063736D1 (en) * 1979-03-27 1983-07-21 Nat Res Dev Improvements in or relating to immunological preparations
US4681762A (en) * 1979-05-23 1987-07-21 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4578458A (en) * 1983-03-23 1986-03-25 Brigham And Women's Hospital Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa
US4738846A (en) * 1984-08-30 1988-04-19 The Salk Institute For Biological Studies Vaccine for vesicular stomatitis virus
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
WO1993006216A1 (en) * 1991-09-26 1993-04-01 Oklahoma Medical Research Foundation Fusion proteins targeted to lysosomes, for the treatment of aids

Also Published As

Publication number Publication date
EP0680513A1 (en) 1995-11-08
CA2154445A1 (en) 1994-08-04
CA2154445C (en) 2007-06-26
GR3031026T3 (en) 1999-12-31
EP0680513B1 (en) 1999-06-02
DE69418856T2 (de) 2000-01-20
JP3581366B2 (ja) 2004-10-27
WO1994017192A2 (en) 1994-08-04
US5633234A (en) 1997-05-27
WO1994017192A3 (en) 1994-09-15
DE69418856D1 (de) 1999-07-08
JPH08505878A (ja) 1996-06-25
ES2132395T3 (es) 1999-08-16
ATE180835T1 (de) 1999-06-15

Similar Documents

Publication Publication Date Title
DK0680513T3 (da) Målretning af immunogener med lysosomer
Zeng et al. Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy
WO2002080851A3 (en) Chimeric vaccines
Barbuto et al. Induction of innate and adaptive immunity by delivery of poly dA: dT to dendritic cells
PL338478A1 (en) Immunological response in respect to hpv antigens induced by compositions comprising a hpv antigen and a shock protein or expression vector capable to express such protein
RU2017138373A (ru) Праймирование иммунного ответа
WO2002012281A3 (en) Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
DE50209178D1 (de) Moduläre Antigen-Transporter Moleküle (MAT-Moleküle) zur Modulierung von Immunreaktionen, zugehörige Konstrukte, Verfahren und Verwendungen
LV12085A (lv) Dendritiskas sunas stimulejosais faktors
Colluru et al. B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines
Thalmensi et al. A DNA telomerase vaccine for canine cancer immunotherapy
Crowley et al. Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH
Nagata et al. Immunization with plasmid DNA encoding MHC class II binding peptide/CLIP-replaced invariant chain (Ii) induces specific helper T cells in vivo: the assessment of Ii p31 and p41 isoforms as vehicles for immunization
WO2006065821A3 (en) Improved dna immunization with recombinase/transposase
Yi et al. Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65
NZ500151A (en) A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
Chowdhury et al. Generation of high titer antisera in rabbits by DNA immunization
Rice et al. DNA fusion vaccines induce epitope-specific cytotoxic CD8+ T cells against human leukemia-associated minor histocompatibility antigens
Bråve et al. Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen
Tan et al. Intramuscular immunization with DNA construct containing Der p 2 and signal peptide sequences primed strong IgE production
ATE395422T1 (de) Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems
He et al. Antigen epitope-expressing cytokines for DNA immunization
Neal et al. Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity
Cafri et al. Development of novel genetic cancer vaccines based on membrane‐attached β2 microglobulin
Johansson et al. Intracellular targeting of CEA results in Th1‐type antibody responses following intradermal genetic vaccination by a needle‐free jet injection device